Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

/PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit...

Related Keywords

Finland ,Stockholm ,Sweden ,Helsinki ,Eteläuomen Läi ,United States ,America ,Edward Haeggstr ,Astellas Pharma Europe ,Christian Jones ,Bluepharma Farmaceutica ,Chris Halling ,Astellas Pharma Inc ,Prnewswire Nanoform Finland Plc ,Danske Bank ,Orientation Marketing Ltd ,Finland Branch ,Finland Plc ,First Subject Visit ,North America ,Chief Executive Officer ,Amorphous Solid Dispersions ,Astellas Pharma ,Chief Commercial ,Orientation Marketing ,Nasdaq First North Growth Market ,Certified Adviser ,Looking Statements ,Financial Statements ,Nanoform ,Medical Pharmaceuticals ,Health Care Amp Hospitals ,Pharmaceuticals ,Surveys ,Olls And Research ,